CAT #: 13080010
BCL1/JH Translocation Assay for Gel Detection
This Research Use Only assay identifies BCL1/JH t(11;14) translocations and is useful for the evaluation of new research and methods in malignancy studies.
Summary and Explanation of the Test
This aberrant BCL1/JH t(11;14) translocation juxtaposes genes of the immunoglobulin heavy chain (IGH) gene on chromosome 14q32 with the cyclin D1 gene on chromosome 11q13. The juxtaposition of IGH-sequences results in the transcriptional activation of cyclin D1.1,2 Cyclin D1 is involved in the regulation of the G1 progression and G1/S transition of the cell cycle.3 Translocation does not lead to expression of a fusion protein. In fact, oncogenesis is due to a promoter/enhancer exchange, wherein the immunoglobulin gene enhancer stimulates the expression of cyclin D1. Overexpression of cyclin D1, in turn, accelerates passage of transformed cells through the G1 phase.
Invivoscribe’s gene rearrangement and translocation assays represent a simple approach to PCR-based clonality testing. These standardized assays were carefully optimized testing positive and negative control samples using multiplex master mixes. Included in this test kit are two (2) master mixes. The BCL1/JH master mix targets the major translocation cluster (MTC) of the BCL1 locus and the joining region of the Ig heavy chain locus. The other master mix, the Specimen Control Size Ladder, targets multiple genes and generates a series of amplicons of 100, 200, 300, 400, and 600 base pair (bp) that can be used to ensure that the quality and quantity of input DNA is adequate to yield a valid result.
This assay tests extracted and purified genomic DNA (gDNA). Common sources of gDNA include:
- 5 cc of peripheral blood, bone marrow biopsy or bone marrow aspirate anti-coagulated with heparin or EDTA. Ship at ambient temperature; OR
- Formalin-fixed paraffin embedded tissue or slides.
1. van Dongen, JJM, et. al. (2003) Leukemia. 17(12):2257-2317.
2. Janssen, JWG, et. al.,(2000) Blood. 95:2691-2698.
3. Shimazaki C, et. al., (1997) International Journal of Hematology. 66(1):111-5.
This assay is based on the EuroClonality/BIOMED-2 Concerted Action BMH4-CT98-3936.
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of positive, negative, and blank controls every time a sample is tested. Ordering, acceptance, and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is for Research Use Only; not for use in diagnostic procedures.
This product is covered by one or more of the following: European Patent Number 1549764, European Patent Number 2418287, European Patent Number 2460889, Japanese Patent Number 4708029, United States Patent 8859748, United States Patent 10280462, and related pending and future applications. All of these patents and applications are licensed exclusively to Invivoscribe®. Additional patents licensed to Invivoscribe® covering some of these products apply elsewhere. Many of these products require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). No license under these patents to use amplification processes or enzymes is conveyed expressly or by implication to the purchaser by the purchase of this product.
©2020 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.